CA2174655A1 - New use of prostaglandins - Google Patents
New use of prostaglandinsInfo
- Publication number
- CA2174655A1 CA2174655A1 CA002174655A CA2174655A CA2174655A1 CA 2174655 A1 CA2174655 A1 CA 2174655A1 CA 002174655 A CA002174655 A CA 002174655A CA 2174655 A CA2174655 A CA 2174655A CA 2174655 A1 CA2174655 A1 CA 2174655A1
- Authority
- CA
- Canada
- Prior art keywords
- prostaglandin
- eye
- prostaglandins
- skin
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
A method for producing a composition containing prostaglandins, derivatives or analogues thereof for increasing pigmentation of tissues or modified tissues, e.g. hair, is disclosed. Among these, derivatives and analogues of prostaglandin F2a and prostaglandin E2 in particular, have been found suitable for the purpose.
Description
WO95/11003 ~1 7 ~ ~ 5 5 PCT/SE~q~ 5 New use of Prostaglandins The present invention is related to the use of prostaglandins and active derivatives or analogues thereof for increasing pigmentation of tissue, for instance eye, skin and hair of animals, including man. The invention also relates to pharmaceutical or cosmetic compositions for said use, as well as the preparation thereof.
The colour of the eye, skin and hair is determined by the amount of melanin in the cells of these structures. Thus, for instance in the eye the colour is determined by the amount of melanin in the melanocytes of the iris. In persons with brown eyes the melanocytes of the iris contain large amounts of melanin whereas in persons with blue eyes the melanocytes of the iris contain only little melanin. When the light in blue eyes is reflected from the pigment epithelium on the back side of the iris the short wave length blue light is not absorbed making the eye colour appear as blue. In persons with brown irises the light is absorbed by the melanin in the melanocytes making the colour appear as brown. In persons with light brown (hazel) or green-brown irises the melanocytes contain more melanin than in persons with blue eyes but less than in persons with brown eyes.
Individuals with little melanin in the cells of the skin have a light pale colour whereas in individuals with much melanin the colour of the skin appears as brown or black depending on the number of melanocytes and the content of melanin in the cells. Whereas in the eye the iridial melanocytes are regarded as continent, i.e. they do not transfer the melanin granules to adjacent cells, in the skin the melanocytes typically transfer the melanin to keratinocytes and they are therefore regarded as incontinent.
The colour of the hair is determined by the melanocytes WO95/11003 ~17 1~ ~ ~ PCT/SE9~J0^~35 located at the dermal papillas. The melanin from these cells is transferred to the cells of the hair matrix and cortex which subsequently keratinize and form the hair.
Thus by stimulating the melanocytes in the vicinity of the hair follicle to produce and donate more melanin to the cells of the hair matrix and cortex it is possible to change the colour of the hair in the direction of dark.
The growth of eyelashes is similar to that of the hair with melanocytes in close vicinity to the eyelash follicle. Consequently, stimulating these melanocytes to produce more melanin will make the eyelashes darker.
The regulation of eye, skin and hair colour generally is not well understood. However, certain hormones such as alpha-melanocyte stimulating hormone (a-MSH), and certain steroid hormones are known to affect pigmentation of the skin. In the normal tanning process of the skin the W
light stimulates directly or indirectly the melanocytes in the skin to produce more melanin which is transferred to the adjacent keratinocytes. There is a continuous proliferation of new keratinocytes and the old ones reach the surface of the skin and by shedding ultimately are removed. Thus, unless the skin is exposed to W light repeatedly the tanning fades away with time. The factors determining the eye colour or hair colour are not known and W light e.g. has no or negligible effect on the eye colour.
Melanin is a large polymer packed in small granules called melanosomes. There are several kinds of melanin.
The most common brown-black melanin is called eumelanin.
Another melanin containing cysteine is pheomelanin.
Typically the colour of pheomelanin is yellow-red.
Individuals with reddish hair have pheomelanin. A third kind of melanin is oximelanin which is black.
We have now unexpectedly found that certain autacoids, more specifically prostaglandins and prostaglandin WO9~/11003 3 2 1 7 4 6 S S PCT/SEg4/0098~
derivatives and analogues can be used for increasing pigmentation of body tissues, like skin and iris of the eye, or modified body tissues like hair and eyelashes, when applied topically on the tissue for long periods of time. So can the colour of the eye be altered due to pigmentation of the iris by application of a prostaglandin. Such experiments have been performed in monkeys and the results have recently been verified in man in clinical trials with a prostaglandin analogue. Most unexpectedly, we have also found that in man prostaglandins can alter the colour of the eyelashes.
Since the eyelashes are analogous with hair a well-based prediction is that similar treatment of the tissue from which hair is developed will result in a corresponding modification of the colour.
Prostaglandins are a group of components derived from unsaturated 20-carbon fatty acids produced normally by the body. Virtually all tissues of the body produce prostaglandins and other eicosanoids. The prostaglandins have a variety of important physiologic functions and are classified as autacoids, autacoid meaning local hormone.
Typically local hormones such as prostaglandins have a consonant effect in the tissue on many different physiological events.
The chemical structure of naturally occurring prostaglandins is illustrated below:
10(~ ~ COOH
'~` / ~ ^ `~O
OH
The prostaglandins consist of a cyclopentane ring, denoted "X" in the above formula, and two side chains, the upper one containing 7 carbon atoms being called the alpha chain and the lower one containing 8 carbon atoms being called WO95/11003 PCT/SE94/0098~
The colour of the eye, skin and hair is determined by the amount of melanin in the cells of these structures. Thus, for instance in the eye the colour is determined by the amount of melanin in the melanocytes of the iris. In persons with brown eyes the melanocytes of the iris contain large amounts of melanin whereas in persons with blue eyes the melanocytes of the iris contain only little melanin. When the light in blue eyes is reflected from the pigment epithelium on the back side of the iris the short wave length blue light is not absorbed making the eye colour appear as blue. In persons with brown irises the light is absorbed by the melanin in the melanocytes making the colour appear as brown. In persons with light brown (hazel) or green-brown irises the melanocytes contain more melanin than in persons with blue eyes but less than in persons with brown eyes.
Individuals with little melanin in the cells of the skin have a light pale colour whereas in individuals with much melanin the colour of the skin appears as brown or black depending on the number of melanocytes and the content of melanin in the cells. Whereas in the eye the iridial melanocytes are regarded as continent, i.e. they do not transfer the melanin granules to adjacent cells, in the skin the melanocytes typically transfer the melanin to keratinocytes and they are therefore regarded as incontinent.
The colour of the hair is determined by the melanocytes WO95/11003 ~17 1~ ~ ~ PCT/SE9~J0^~35 located at the dermal papillas. The melanin from these cells is transferred to the cells of the hair matrix and cortex which subsequently keratinize and form the hair.
Thus by stimulating the melanocytes in the vicinity of the hair follicle to produce and donate more melanin to the cells of the hair matrix and cortex it is possible to change the colour of the hair in the direction of dark.
The growth of eyelashes is similar to that of the hair with melanocytes in close vicinity to the eyelash follicle. Consequently, stimulating these melanocytes to produce more melanin will make the eyelashes darker.
The regulation of eye, skin and hair colour generally is not well understood. However, certain hormones such as alpha-melanocyte stimulating hormone (a-MSH), and certain steroid hormones are known to affect pigmentation of the skin. In the normal tanning process of the skin the W
light stimulates directly or indirectly the melanocytes in the skin to produce more melanin which is transferred to the adjacent keratinocytes. There is a continuous proliferation of new keratinocytes and the old ones reach the surface of the skin and by shedding ultimately are removed. Thus, unless the skin is exposed to W light repeatedly the tanning fades away with time. The factors determining the eye colour or hair colour are not known and W light e.g. has no or negligible effect on the eye colour.
Melanin is a large polymer packed in small granules called melanosomes. There are several kinds of melanin.
The most common brown-black melanin is called eumelanin.
Another melanin containing cysteine is pheomelanin.
Typically the colour of pheomelanin is yellow-red.
Individuals with reddish hair have pheomelanin. A third kind of melanin is oximelanin which is black.
We have now unexpectedly found that certain autacoids, more specifically prostaglandins and prostaglandin WO9~/11003 3 2 1 7 4 6 S S PCT/SEg4/0098~
derivatives and analogues can be used for increasing pigmentation of body tissues, like skin and iris of the eye, or modified body tissues like hair and eyelashes, when applied topically on the tissue for long periods of time. So can the colour of the eye be altered due to pigmentation of the iris by application of a prostaglandin. Such experiments have been performed in monkeys and the results have recently been verified in man in clinical trials with a prostaglandin analogue. Most unexpectedly, we have also found that in man prostaglandins can alter the colour of the eyelashes.
Since the eyelashes are analogous with hair a well-based prediction is that similar treatment of the tissue from which hair is developed will result in a corresponding modification of the colour.
Prostaglandins are a group of components derived from unsaturated 20-carbon fatty acids produced normally by the body. Virtually all tissues of the body produce prostaglandins and other eicosanoids. The prostaglandins have a variety of important physiologic functions and are classified as autacoids, autacoid meaning local hormone.
Typically local hormones such as prostaglandins have a consonant effect in the tissue on many different physiological events.
The chemical structure of naturally occurring prostaglandins is illustrated below:
10(~ ~ COOH
'~` / ~ ^ `~O
OH
The prostaglandins consist of a cyclopentane ring, denoted "X" in the above formula, and two side chains, the upper one containing 7 carbon atoms being called the alpha chain and the lower one containing 8 carbon atoms being called WO95/11003 PCT/SE94/0098~
2~ 74655 the omega chain. The end of the alpha chain is normally a carboxylic acid moiety. The side chains can contain l to 3 double bonds, most frequently 2, the double bonds being situated between carbon atoms 5 and 6 on the alpha chain as well as 13 and 14 on the omega chain. The double bond on the alpha chain exhibits cis-configuration, whereas the double bond on the omega chain exhibits trans-configuration. Essential for biological activity is furthermore the substituent group on carbon 15 in the omega chain. In naturally occurring prostaglandins this substituent is hydroxyl. The configuration and functionalities of the cyclopentane ring (X) is important for selectivity to different prostaglandin receptors and the various configurations are depicted below:
O O O OH
A B C O D
O OH
OH E OH F J
Accordingly, prostaglandins are given suffixes A, B, C, D, E, F or J depending on the functionalities of the five membered ring, that is the configuration and substituents of the cyclopentane ring. Noteworthy is that prostaglandins A, B and C probably are not naturally occurring and represent artificial prostaglandins.
Nevertheless they exert considerable biologic activity. In order to enhance delivery and to improve chemical stability of prostaglandins the carboxylic acid moiety on the omega chain can be esterified, for instance with alkyl groups containing l-lO carbons, especially 1-6 carbons
O O O OH
A B C O D
O OH
OH E OH F J
Accordingly, prostaglandins are given suffixes A, B, C, D, E, F or J depending on the functionalities of the five membered ring, that is the configuration and substituents of the cyclopentane ring. Noteworthy is that prostaglandins A, B and C probably are not naturally occurring and represent artificial prostaglandins.
Nevertheless they exert considerable biologic activity. In order to enhance delivery and to improve chemical stability of prostaglandins the carboxylic acid moiety on the omega chain can be esterified, for instance with alkyl groups containing l-lO carbons, especially 1-6 carbons
3 5 2 1 7 4 fi 5 ~ PCT/SEg4/00985 .
e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl or benzyl. Such esterified prodrugs of prostaglandins have been described in several patents and patent applications (see for instance EP 093380, EP 0364417 and W092/02496). Depending on the specific prostaglandin analogue other derivatives such as salts, e.g. the sodium salt, may also be used.
It is accordingly one objective of the invention to provide a method for increasing the pigmentation of body tissues like the eye and the skin as well as modified body tissues like the hair and the eyelashes by administration of a prostaglandin or an active analogue or derivative thereof, for instance in certain senile and/or pathological conditions. Such conditions comprise e.g.
- depigmentation of the iris causing the iris to become lighter, - white hair, a condition common among elderly people, and a typical senile change generally perceived negative, and - vitiligo, a typical disease entity in the skin with hypopigmentation. Vitiligo can occur in many different parts of the body and is perceived as a cosmetic and psychological problem.
According to the mechanism discussed above, which however doesn't limit the invention in any way if found incorrect or uncomplete, the invention can alternatively be defined as providing a method for stimulating melanocytes to produce increased amounts of melanin-type substances in animals including man.
Typically the prostaglandins are applied repeatedly for a sustained period of time topically on the part of the body to be treated, for instance the eye, skin or scalp. The active component, the prostaglandin, can be administered by means of aqueous solutions or oil solutions as well as in liniments, creams, ointments, shampoos or in patches, depending on the part of the body to be treated. The WO95/11003 ~1 7 4 65 5 PCT/SEg~ 9~5 formulations thus have to be adapted to the specific physiological requirements of the organ or tissue to be treated. The solubility and/or stability of the prostaglandin compound may be increased by adding substances forming a complex with the prostaglandin, for instance cyclodextrin-type substances or other compounds known to form complexes, such as inclusion complexes, with hydrophobic compounds.
It is also an objective of the present invention to provide a composition containing an effective amount of at least one prostaglandin or an active analogue or derivative thereof in a physiologically, and pharmacological acceptable carrier for increasing the pigmentation of body tissues like the eye and the skin as well as modified body tissues like the hair and the eyelashes.
For topical use on the eye and the eye lids, the prostaglandins as well as their derivatives and analogues, including esters and salts, can be formulated in aqueous solutions, creams, ointments or oils exhibiting physiologically acceptable osmolarity by addition of pharmacologically acceptable buffers and salts. Such formulations may or may not, depending on the dispenser, contain preservatives such as benzalkonium chloride, chlorhexidine, chlorobutanol, parahydroxybenzoic acids and phenylmercuric salts such as nitrate, chloride, acetate, and borate, or antioxidants, as well as additives like EDTA, sorbitol, boric acid etc. as additives. Furthermore, particularly aqueous solutions may contain viscosity increasing agents such as polysaccharides, e.g.
methylcellulose, mucopolysaccharides, e.g. hyaluronic acid and chondroitin sulfate, or polyalcoholes, e.g.
polyvinylalcohol. Various slow releasing gels and matrices may also be employed as well as soluble and insoluble ocular inserts, for instance based on substances forming in-situ gels. Depending on the actual formulation and WO95/11003 7 2 1 7 ~ 6 5 S PCT/SEg4~0985 prostaglandin analogue to be used various amounts of the drug and different dose regimens may be employed.
Typically the daily amount of prostaglandin for treatment of the eye might be O.l-lO00 ~g/eye, particularly l-lO0 ~
g/eye. To achieve the daily amount of medication depending on the formulation, the prostaglandins may be administered once or several times daily.
For topical use on the skin and the scalp the prostaglandin component can advantageously be formulated using ointments, creams, liniments or patches as carrier.
Also these formulations may or may not contain preservatives depending on the dispenser. Such preservatives comprise as mentioned above e.g. methyl-, propyl- or butyl-parahydroxybenzoic acid, betain, chlorhexidine, benzalkonium chloride, and alike. Various matrices for slow release delivery may also be used.
Typically the dose to be applied on the scalp is in the range of O.OOOl-lO0 mg/day, esp. O.OOl-lO0 mg/day, depending on the prostaglandin and the formulation. In a preferred embodiment the dose is O.OOl-lO mg/day and especially O.Ol-lO mg/day. For the treatment of vitiligo and other skin disorders typically a dose of O.OOOl-lO
mg/square decimetre/day, like O.OOl-l and esp. O.Ol-l mg/square decimetre/day is employed. To achieve the daily amount of medication depending on the formulation, the prostaglandin may be administered once or several times daily with or without antioxidants.
Several different prostaglandins may be employed to achieve the therapeutic effect on pigmentation in the types of tissues discussed above, e.g. the eye, skin and hair. Particularly prostaglandins of the A, F and E types have been found efficacious. To minimize side effects such as irritation and redness of the eye and skin it may be suitable to use prostaglandin derivatives or analogues which have been found to exert less side effects such as phenyl- and other ring-substituted prostaglandin 2~746~) 8 derivatives described e.g. in PCT patent publication no:
W090/02553. Prostaglandins exhibiting high pharmacological activity and no or only very small side effects such as 17-phenyl-18,19,20-trinor-PGF2a and its carboxylic acid esters may be particularly useful if large areas e.g. of the skin are to be treated. Other prostaglandin analogues exhibiting good therapeutic index may also be used.
Generally, since hair growth is slow, the prostaglandins have to be used for sustained periods of time, typically half a year to one year, and if the coloration of the skin or hair is to be preserved the prostaglandin has to be used chronically. It is also possible to use the formulation containing prostaglandins during long term treatment intermittently, e.g. once or twice a week, once every second week or e.g. continuously for a month followed by a month without treatment etc, depending on the potency of the particular prostaglandin.
To achieve increased pigmentation of the iris the prostaglandin formulation has to be administered regularly at least for 3 months or longer. However, in the eye after achieving a certain degree of pigmentation, the prostaglandin can be administered less frequently to maintain the new state of pigmentation e.g. once a week or once a month or possible even with longer intervals or alternatively with intermittent periods of frequent treatment, e.g. once daily for a month which is followed by a period of 3-12 months of no treatment, followed again by treatment once daily for one month, etc. It may also be possible that the colour change in the iris induced by prostaglandin treatment is permanent and no continuing or intermittent treatment is necessary.
The invention is exemplified with the following non-limiting experiments and clinical data:
WO95/11003 pcTlsE~ sn~
9 2174S5~
Synthesis and formulation of prostaglandin derivatives.
PGF2~ isopropyl ester This compound was prepared from the commercially available corresponding acid, PGF2a The acid was esterified in acetone with isopropyl iodide in the presence of D~3U
according to a method described by Grundo R (Organic Prep and Proc Int 1980, 12, 225-228) as a white crystalline product: mp 59-60 C; yield (77%); Rf = 0.29 (acetone :
EtOAc 1:1); lH NMR (CDC13) d 0.89(t, 3H), 1.2 (d, 6H), 1.3 (m, 6H), 1.5 (m, 3H), 1.68 (m, 2H), 1.8 (m,2H), 2.05-2.42 (m, 8H), 2.94 (d, lH), 3.94 (m, lH), 4.06 (q, lH),
e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, neopentyl or benzyl. Such esterified prodrugs of prostaglandins have been described in several patents and patent applications (see for instance EP 093380, EP 0364417 and W092/02496). Depending on the specific prostaglandin analogue other derivatives such as salts, e.g. the sodium salt, may also be used.
It is accordingly one objective of the invention to provide a method for increasing the pigmentation of body tissues like the eye and the skin as well as modified body tissues like the hair and the eyelashes by administration of a prostaglandin or an active analogue or derivative thereof, for instance in certain senile and/or pathological conditions. Such conditions comprise e.g.
- depigmentation of the iris causing the iris to become lighter, - white hair, a condition common among elderly people, and a typical senile change generally perceived negative, and - vitiligo, a typical disease entity in the skin with hypopigmentation. Vitiligo can occur in many different parts of the body and is perceived as a cosmetic and psychological problem.
According to the mechanism discussed above, which however doesn't limit the invention in any way if found incorrect or uncomplete, the invention can alternatively be defined as providing a method for stimulating melanocytes to produce increased amounts of melanin-type substances in animals including man.
Typically the prostaglandins are applied repeatedly for a sustained period of time topically on the part of the body to be treated, for instance the eye, skin or scalp. The active component, the prostaglandin, can be administered by means of aqueous solutions or oil solutions as well as in liniments, creams, ointments, shampoos or in patches, depending on the part of the body to be treated. The WO95/11003 ~1 7 4 65 5 PCT/SEg~ 9~5 formulations thus have to be adapted to the specific physiological requirements of the organ or tissue to be treated. The solubility and/or stability of the prostaglandin compound may be increased by adding substances forming a complex with the prostaglandin, for instance cyclodextrin-type substances or other compounds known to form complexes, such as inclusion complexes, with hydrophobic compounds.
It is also an objective of the present invention to provide a composition containing an effective amount of at least one prostaglandin or an active analogue or derivative thereof in a physiologically, and pharmacological acceptable carrier for increasing the pigmentation of body tissues like the eye and the skin as well as modified body tissues like the hair and the eyelashes.
For topical use on the eye and the eye lids, the prostaglandins as well as their derivatives and analogues, including esters and salts, can be formulated in aqueous solutions, creams, ointments or oils exhibiting physiologically acceptable osmolarity by addition of pharmacologically acceptable buffers and salts. Such formulations may or may not, depending on the dispenser, contain preservatives such as benzalkonium chloride, chlorhexidine, chlorobutanol, parahydroxybenzoic acids and phenylmercuric salts such as nitrate, chloride, acetate, and borate, or antioxidants, as well as additives like EDTA, sorbitol, boric acid etc. as additives. Furthermore, particularly aqueous solutions may contain viscosity increasing agents such as polysaccharides, e.g.
methylcellulose, mucopolysaccharides, e.g. hyaluronic acid and chondroitin sulfate, or polyalcoholes, e.g.
polyvinylalcohol. Various slow releasing gels and matrices may also be employed as well as soluble and insoluble ocular inserts, for instance based on substances forming in-situ gels. Depending on the actual formulation and WO95/11003 7 2 1 7 ~ 6 5 S PCT/SEg4~0985 prostaglandin analogue to be used various amounts of the drug and different dose regimens may be employed.
Typically the daily amount of prostaglandin for treatment of the eye might be O.l-lO00 ~g/eye, particularly l-lO0 ~
g/eye. To achieve the daily amount of medication depending on the formulation, the prostaglandins may be administered once or several times daily.
For topical use on the skin and the scalp the prostaglandin component can advantageously be formulated using ointments, creams, liniments or patches as carrier.
Also these formulations may or may not contain preservatives depending on the dispenser. Such preservatives comprise as mentioned above e.g. methyl-, propyl- or butyl-parahydroxybenzoic acid, betain, chlorhexidine, benzalkonium chloride, and alike. Various matrices for slow release delivery may also be used.
Typically the dose to be applied on the scalp is in the range of O.OOOl-lO0 mg/day, esp. O.OOl-lO0 mg/day, depending on the prostaglandin and the formulation. In a preferred embodiment the dose is O.OOl-lO mg/day and especially O.Ol-lO mg/day. For the treatment of vitiligo and other skin disorders typically a dose of O.OOOl-lO
mg/square decimetre/day, like O.OOl-l and esp. O.Ol-l mg/square decimetre/day is employed. To achieve the daily amount of medication depending on the formulation, the prostaglandin may be administered once or several times daily with or without antioxidants.
Several different prostaglandins may be employed to achieve the therapeutic effect on pigmentation in the types of tissues discussed above, e.g. the eye, skin and hair. Particularly prostaglandins of the A, F and E types have been found efficacious. To minimize side effects such as irritation and redness of the eye and skin it may be suitable to use prostaglandin derivatives or analogues which have been found to exert less side effects such as phenyl- and other ring-substituted prostaglandin 2~746~) 8 derivatives described e.g. in PCT patent publication no:
W090/02553. Prostaglandins exhibiting high pharmacological activity and no or only very small side effects such as 17-phenyl-18,19,20-trinor-PGF2a and its carboxylic acid esters may be particularly useful if large areas e.g. of the skin are to be treated. Other prostaglandin analogues exhibiting good therapeutic index may also be used.
Generally, since hair growth is slow, the prostaglandins have to be used for sustained periods of time, typically half a year to one year, and if the coloration of the skin or hair is to be preserved the prostaglandin has to be used chronically. It is also possible to use the formulation containing prostaglandins during long term treatment intermittently, e.g. once or twice a week, once every second week or e.g. continuously for a month followed by a month without treatment etc, depending on the potency of the particular prostaglandin.
To achieve increased pigmentation of the iris the prostaglandin formulation has to be administered regularly at least for 3 months or longer. However, in the eye after achieving a certain degree of pigmentation, the prostaglandin can be administered less frequently to maintain the new state of pigmentation e.g. once a week or once a month or possible even with longer intervals or alternatively with intermittent periods of frequent treatment, e.g. once daily for a month which is followed by a period of 3-12 months of no treatment, followed again by treatment once daily for one month, etc. It may also be possible that the colour change in the iris induced by prostaglandin treatment is permanent and no continuing or intermittent treatment is necessary.
The invention is exemplified with the following non-limiting experiments and clinical data:
WO95/11003 pcTlsE~ sn~
9 2174S5~
Synthesis and formulation of prostaglandin derivatives.
PGF2~ isopropyl ester This compound was prepared from the commercially available corresponding acid, PGF2a The acid was esterified in acetone with isopropyl iodide in the presence of D~3U
according to a method described by Grundo R (Organic Prep and Proc Int 1980, 12, 225-228) as a white crystalline product: mp 59-60 C; yield (77%); Rf = 0.29 (acetone :
EtOAc 1:1); lH NMR (CDC13) d 0.89(t, 3H), 1.2 (d, 6H), 1.3 (m, 6H), 1.5 (m, 3H), 1.68 (m, 2H), 1.8 (m,2H), 2.05-2.42 (m, 8H), 2.94 (d, lH), 3.94 (m, lH), 4.06 (q, lH),
4.18 (q, lH), 5 (sept, lH), 5.34-5.45 (m, 2H), 5.46-5.52 (q, lH), 5.54-5.60 (q, lH); 13C NMR (CDCl3) dl73.39, 135.19, 132.56, 129.72, 129.00, 78.05, 72.99, 72.89, 67.64, 55.83, 50.46, 42.87, 37.27, 34.06, 31.74, 26.63, 25.68, 25.21, 24.90, 22.61, 21.85, 21.84, 14.02.
PGE~ isopropyl ester To a solution of PGE2 (PGE2 obtained from Chinoin) (100 mg, 0.28 mmoL) in acetonitrile (10 mL), were added ethyl diisopropyl amine (161 mg, 1.3mmoL) and isopropyl iodide (380 mg, 2.3 mmoL). The reaction mixture was warmed to 60-65 C for 2-3 hours (TLC monitoring). The solution was diluted with diethyl ether (30 mL) and washed with water (20 mL).The water layer was extracted with diethyl ether (30 mL). The combined organic layer was washed with brine (2XlOmL), citric acid 5% (2X15 mL), and sodium hydrogen carbonate 5% (3X15 mL). The organic phase was dried on magnesium sulfate, and filtered. The solvent was removed in vacuum to give a colourless oil, which was purified by column chromatography on silica gel using diethyl ether:
ethyl acetate (3:1) as eluent, this afforded a colourless oil of PGE2 isopropyl ester: yield 72mg (64%).
NMR data lH NMR (CDCL3) ~ 0.9(3H, m); 1.22(6H,d); 1.3 (6H, m); 1.4-1.5(2H, m); 1.6-1.7 (2H, m); 2.05 (q, 2H); 2.2-2.4(6H, m);
WO95/11003 ~ 1 7 4 6 ~ ~ ~o PCT/SE94/00985 2.7(1H, m,); 4.05~1H, q); 4.10(1H, q); 5.0(1H, sept)5.30 (lH, m); 5.43 (lH, m); 5.54(lH, q); 5.64(lH, q).
13,14-dihydro-17-phenyl-18,19,20-trinor PGF2~ isopropyl ester was prepared according to the method disclosed in PCT publication W092/02496, which is hereby incorporated by reference.
Effect of prostaglandins on iridial pigmentation in animals.
Cynomolgus monkeys were used. The monkeys were treated topically once daily for 4-12 months with either of the following prostaglandins:
- PGF2a-isopropylester 0.5 ~g/day, 2 ~g/day and 6 ~g/day;
- PGE2-isopropylester 3 ~g/day; and - 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropyl-ester 2 ~g/day, 6 ~g/day and 20 ~g/day.
The contralateral eye received the vehicle only and served as a control. The frequency of increased iridial pigmentation is shown in Table I. The increase in iridial pigmentation was mostly classified as mild to moderate but in all groups some animals exhibited marked pigmentation.
Thus, PGE2-isopropylester, PGF2a-isopropylester as well as 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester all increased iridial pigmentation in an animal model closely reminiscent of the human eye.
WO95/11003 11 2 1 7 4 ~ ~ 5 PcTlsE94loo98~
-Table I. Frequency of increased iridial pigmentation in monkeys after treatment with prostaglandin for 4-12 months.
Prostaglandin n Dose Duration Animals with of treatm. pigmentation (ug/eye) (months) PGF2a-isopropylester 4 0.5 4 2/4 4 2.0 4 1/4 4 6.0 4 3/4 PGE2-isopropylester 4 3.0 4 2/9 13,14-dihydro-17- 10 2.0 12 4/10 phenyl-18,19,20- 10 6.0 12 6/10 trinor-PGF2a~ 10 20 12 8/10 isopropylester After 4-12 months of continuous treatment with prostaglandins the animals were killed and histological sections of the eyes were prepared. Light microscopical pictures clearly demonstrated increased amount of melanin in the melanocytes of the iris.
Effect of prostaglandin on iridial pigmentation in man The results in monkeys have been confirmed in man in clinical trials performed with 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester eye drops. After 4.5 to 6 months of continuous treatment with the drug at a dose of approximately 1.5 ~g/eye/day (0.005~ ophthalmic solution) a change in iridial pigmentation has been observed in patients with green-brown irides. The change in eye colour has been documented with colour photographs taken before treatment and during treatment at regular intervals. The increase in pigmentation has been WO95/11003 ~ l 7 ~ 6 ~ ~ 12 PCT/SE94/00985 classified as mild to moderate. In several of the cases the iris has exhibited depigmented spots or larger areas before treatment, which have been repigmented during treatment with the drug. Thus it is possible that prostaglandin treatment restores normal pigmentation in patients suffering from senile depigmentation. Results obtained in the clinical trials are presented in Table II.
Table II. Occurrence of increased pigmentation of the iris during treatment with 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester in patients with elevated intraocular pressure.
Colour of the iris Duration Dose Frequency of treatm.
(months) (ug/eye)(~) Green-brown 4.5-6 1.5 > 20 These results clearly demonstrate that the iridial pigmentation can be increased both in monkeys and in man.
A prerequisite for increased pigmentation of the iris in man seems to be a yellow-brown, green-brown or blue/grey-brown colour. There is no other drug known which is able to change the pigmentation of the iris in man.
In addition to the increase in iridial pigmentation in certain patients during treatment with 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester eye drops, we have also noticed that some patients get darker eyelashes.
The probable explanation for this is that during topical treatment with this prostaglandin analogue part of the drug reaches the follicles of the eyelashes in the eye lids. Thus the melanocytes at the eye lash follicles are stimulated to produce and donate more pigment to the WO95/11003 1 21 7 4 6 ~ ~ PCT/SE94/00985 matrix and cortex cells of the eyelashes and therefore the eyelashes get darker. Since the turnover rate of new eyelashes is approximately 150 days this effect can only be detected during treatment with the drug for long enough periods, approximately 1/2 year.
The implication of the finding with increased pigmentation of the eye-lashes is that hair in general can be made darker with prostaglandins. Thus the hair of the scalp in principle can be treated in the same way with prostaglandins to become darker. Since the hair has a growth rate of approximately 0.5-1 cm/month treatment to convert the colour of the hair will take 6-12 months or longer and to maintain the colour the treatment must continue at regular intervals or intermittently. This indication of prostaglandins may be employed e.g. in individuals suffering from grey or white hair.
Since melanocytes both in the iris and at the eyelash ~hair) follicles of the eye lids can be stimulated to produce more melanin by prostaglandins it is evident that melanocytes also in the skin elsewhere can be stimulated by prostaglandins. Thus, a tanning of the skin can be achieved analogously. Such tanning may be desirable from a simple cosmetic point of view but may also be important from a therapeutical point of view in the treatment of certain pathological conditions in the skin such as hypopigmentation e.g. vitiligo.
PGE~ isopropyl ester To a solution of PGE2 (PGE2 obtained from Chinoin) (100 mg, 0.28 mmoL) in acetonitrile (10 mL), were added ethyl diisopropyl amine (161 mg, 1.3mmoL) and isopropyl iodide (380 mg, 2.3 mmoL). The reaction mixture was warmed to 60-65 C for 2-3 hours (TLC monitoring). The solution was diluted with diethyl ether (30 mL) and washed with water (20 mL).The water layer was extracted with diethyl ether (30 mL). The combined organic layer was washed with brine (2XlOmL), citric acid 5% (2X15 mL), and sodium hydrogen carbonate 5% (3X15 mL). The organic phase was dried on magnesium sulfate, and filtered. The solvent was removed in vacuum to give a colourless oil, which was purified by column chromatography on silica gel using diethyl ether:
ethyl acetate (3:1) as eluent, this afforded a colourless oil of PGE2 isopropyl ester: yield 72mg (64%).
NMR data lH NMR (CDCL3) ~ 0.9(3H, m); 1.22(6H,d); 1.3 (6H, m); 1.4-1.5(2H, m); 1.6-1.7 (2H, m); 2.05 (q, 2H); 2.2-2.4(6H, m);
WO95/11003 ~ 1 7 4 6 ~ ~ ~o PCT/SE94/00985 2.7(1H, m,); 4.05~1H, q); 4.10(1H, q); 5.0(1H, sept)5.30 (lH, m); 5.43 (lH, m); 5.54(lH, q); 5.64(lH, q).
13,14-dihydro-17-phenyl-18,19,20-trinor PGF2~ isopropyl ester was prepared according to the method disclosed in PCT publication W092/02496, which is hereby incorporated by reference.
Effect of prostaglandins on iridial pigmentation in animals.
Cynomolgus monkeys were used. The monkeys were treated topically once daily for 4-12 months with either of the following prostaglandins:
- PGF2a-isopropylester 0.5 ~g/day, 2 ~g/day and 6 ~g/day;
- PGE2-isopropylester 3 ~g/day; and - 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropyl-ester 2 ~g/day, 6 ~g/day and 20 ~g/day.
The contralateral eye received the vehicle only and served as a control. The frequency of increased iridial pigmentation is shown in Table I. The increase in iridial pigmentation was mostly classified as mild to moderate but in all groups some animals exhibited marked pigmentation.
Thus, PGE2-isopropylester, PGF2a-isopropylester as well as 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester all increased iridial pigmentation in an animal model closely reminiscent of the human eye.
WO95/11003 11 2 1 7 4 ~ ~ 5 PcTlsE94loo98~
-Table I. Frequency of increased iridial pigmentation in monkeys after treatment with prostaglandin for 4-12 months.
Prostaglandin n Dose Duration Animals with of treatm. pigmentation (ug/eye) (months) PGF2a-isopropylester 4 0.5 4 2/4 4 2.0 4 1/4 4 6.0 4 3/4 PGE2-isopropylester 4 3.0 4 2/9 13,14-dihydro-17- 10 2.0 12 4/10 phenyl-18,19,20- 10 6.0 12 6/10 trinor-PGF2a~ 10 20 12 8/10 isopropylester After 4-12 months of continuous treatment with prostaglandins the animals were killed and histological sections of the eyes were prepared. Light microscopical pictures clearly demonstrated increased amount of melanin in the melanocytes of the iris.
Effect of prostaglandin on iridial pigmentation in man The results in monkeys have been confirmed in man in clinical trials performed with 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester eye drops. After 4.5 to 6 months of continuous treatment with the drug at a dose of approximately 1.5 ~g/eye/day (0.005~ ophthalmic solution) a change in iridial pigmentation has been observed in patients with green-brown irides. The change in eye colour has been documented with colour photographs taken before treatment and during treatment at regular intervals. The increase in pigmentation has been WO95/11003 ~ l 7 ~ 6 ~ ~ 12 PCT/SE94/00985 classified as mild to moderate. In several of the cases the iris has exhibited depigmented spots or larger areas before treatment, which have been repigmented during treatment with the drug. Thus it is possible that prostaglandin treatment restores normal pigmentation in patients suffering from senile depigmentation. Results obtained in the clinical trials are presented in Table II.
Table II. Occurrence of increased pigmentation of the iris during treatment with 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester in patients with elevated intraocular pressure.
Colour of the iris Duration Dose Frequency of treatm.
(months) (ug/eye)(~) Green-brown 4.5-6 1.5 > 20 These results clearly demonstrate that the iridial pigmentation can be increased both in monkeys and in man.
A prerequisite for increased pigmentation of the iris in man seems to be a yellow-brown, green-brown or blue/grey-brown colour. There is no other drug known which is able to change the pigmentation of the iris in man.
In addition to the increase in iridial pigmentation in certain patients during treatment with 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2a-isopropylester eye drops, we have also noticed that some patients get darker eyelashes.
The probable explanation for this is that during topical treatment with this prostaglandin analogue part of the drug reaches the follicles of the eyelashes in the eye lids. Thus the melanocytes at the eye lash follicles are stimulated to produce and donate more pigment to the WO95/11003 1 21 7 4 6 ~ ~ PCT/SE94/00985 matrix and cortex cells of the eyelashes and therefore the eyelashes get darker. Since the turnover rate of new eyelashes is approximately 150 days this effect can only be detected during treatment with the drug for long enough periods, approximately 1/2 year.
The implication of the finding with increased pigmentation of the eye-lashes is that hair in general can be made darker with prostaglandins. Thus the hair of the scalp in principle can be treated in the same way with prostaglandins to become darker. Since the hair has a growth rate of approximately 0.5-1 cm/month treatment to convert the colour of the hair will take 6-12 months or longer and to maintain the colour the treatment must continue at regular intervals or intermittently. This indication of prostaglandins may be employed e.g. in individuals suffering from grey or white hair.
Since melanocytes both in the iris and at the eyelash ~hair) follicles of the eye lids can be stimulated to produce more melanin by prostaglandins it is evident that melanocytes also in the skin elsewhere can be stimulated by prostaglandins. Thus, a tanning of the skin can be achieved analogously. Such tanning may be desirable from a simple cosmetic point of view but may also be important from a therapeutical point of view in the treatment of certain pathological conditions in the skin such as hypopigmentation e.g. vitiligo.
Claims (10)
1. Use of an active amount of a prostaglandin or an active derivative or analogue thereof for manufacturing a composition for increasing the pigmentation of a tissue or modified tissue, e.g. the iris, skin and hair.
2. Use according to claim 1 in which the prostaglandin is a derivative of PGF2.alpha..
3. Use according to claim 1 in which the prostaglandin is a derivative of PGE2.
9. Use according to claim 2 in which the prostaglandin is a 17-phenyl-18,19,20-trinor-PGF2.alpha. derivative.
5. Use according to claim 1 in which the prostaglandin derivative is an ester of 13,14-dihydro-17-phenyl-18,19,20-trinor-pGF2.alpha..
6. A method for increasing the pigmentation of tissue or modified tissue, e.g. the iris, skin and hair, comprising administration of an active prostaglandin or a derivative or analogue thereof, as defined in any one of claims 1-5, in a physiologically acceptable formulation to said tissue.
7. Method according to claim 6 in which the prostaglandin is administered to the eye in an amount of 0.1-100 µg/eye daily or at regular intervals.
8. Method according to claim 6 in which the prostaglandin is administered to the scalp in an amount of 0.001-10 mg daily or at regular intervals.
9. Method according to claim 6 in which the prostaglandin is administered to the skin in an amount of approximately 0.0001-10 mg/square decimetre daily or at regular intervals.
10. A pharmaceutical or cosmetic composition containing an active prostaglandin or a derivative or analogue thereof, as defined in any one of claims 1-5, and a physiologically acceptable carrier, e.g. a solution, ointment, cream, liniment or a patch.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9303444-5 | 1993-10-20 | ||
| SE9303444A SE9303444D0 (en) | 1993-10-20 | 1993-10-20 | New use of prostaglandins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2174655A1 true CA2174655A1 (en) | 1995-04-27 |
Family
ID=20391475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002174655A Abandoned CA2174655A1 (en) | 1993-10-20 | 1994-10-19 | New use of prostaglandins |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0724425A1 (en) |
| JP (1) | JPH09504021A (en) |
| AU (1) | AU8008694A (en) |
| CA (1) | CA2174655A1 (en) |
| SE (1) | SE9303444D0 (en) |
| WO (1) | WO1995011003A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263054B2 (en) | 2002-02-04 | 2012-09-11 | Allergan, Inc. | Method of enhancing hair growth |
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US9750750B2 (en) | 2009-11-09 | 2017-09-05 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998000100A1 (en) * | 1996-07-03 | 1998-01-08 | The Board Of Regents Of The University Of Oklahoma | Enhancement of skin pigmentation by prostaglandins |
| AU750039B2 (en) * | 1997-02-04 | 2002-07-11 | Murray A. Johnstone | Method of enhancing hair growth |
| CA2364948C (en) | 1999-03-05 | 2011-04-26 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
| US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| FR2812192B1 (en) * | 2000-07-28 | 2003-01-31 | Oreal | USE OF PROSTAGLANDIN EP-3 RECEPTOR ANTAGONISTS AS A COSMETIC AGENT FOR MITIGATING, REDUCING OR STOPPING HAIR AND HAIR LOSS |
| FR2812190B1 (en) * | 2000-07-28 | 2003-01-31 | Oreal | USE OF NON-PROSTANOIC AGONISTS OF EP-2 AND / OR EP-4 PROSTAGLANDIN RECEPTORS AS A COSMETIC AGENT FOR MITIGATING, DECREASING OR STOPPING HAIR AND HAIR LOSS |
| KR100437873B1 (en) | 2001-05-08 | 2004-06-26 | 연성정밀화학(주) | Process for preparing prostaglandin derivatives and stereospecific starting material thereof |
| JP4584908B2 (en) | 2003-02-12 | 2010-11-24 | ロレアル | Use of inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of skin or skin appendages |
| US7326717B2 (en) | 2003-05-06 | 2008-02-05 | L'oreal | Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof |
| TWI495471B (en) | 2003-08-12 | 2015-08-11 | R Tech Ueno Ltd | Composition and method for promoting hair growth |
| FR2907682B1 (en) | 2006-10-26 | 2012-12-07 | Vincience | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING AS AN ACTIVE INGREDIENT AT LEAST ONE PEPTIDE AND THE USE OF THIS PEPTIDE. |
| FR2920309B1 (en) | 2007-08-28 | 2010-05-28 | Galderma Res & Dev | USE OF TRAVOPROST TO TREAT THE FALL OF HAIR |
| CN102143753B (en) * | 2008-09-04 | 2013-07-03 | 参天制药株式会社 | Hair growth promoter containing 15, 15-difluoroprostaglandin F2 alphaderivative as effective component is provided |
| WO2010064203A1 (en) | 2008-12-02 | 2010-06-10 | L'oreal | Combination of reduced glutathione and amino acids for improving the quality of the hair in women |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| FR2949052B1 (en) | 2009-08-13 | 2015-03-27 | Oreal | PROCESS FOR COSMETIC TREATMENT OF SCALP. |
| FR2951938B1 (en) | 2009-10-30 | 2012-01-06 | Oreal | USE OF A PUNICA GRANATUM EXTRACT TO COMBAT CANITIS |
| FR2978659B1 (en) * | 2011-08-05 | 2014-01-10 | Oreal | USE OF CANNABINOID COMPOUNDS FOR STIMULATING MELANOGENESIS |
| EP3295940A1 (en) | 2012-04-16 | 2018-03-21 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| FR2999932B1 (en) | 2012-12-21 | 2020-01-31 | Société des Produits Nestlé S.A. | USE OF PROBIOTIC MICROORGANISMS AS A MELANIN SYNTHESIS AGENT |
| FR2999931A1 (en) | 2012-12-21 | 2014-06-27 | Oreal | USE OF PROBIOTIC MICROORGANISMS AS AN AGENT PROMOTING MELANIN SYNTHESIS |
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| AU2016229918B2 (en) | 2015-03-08 | 2020-10-29 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating fibrosis |
| JP2020502070A (en) | 2016-11-30 | 2020-01-23 | ケース ウエスタン リザーブ ユニバーシティ | Combinations of 15-PGDH inhibitors with corticosteroids and / or TNF inhibitors and uses thereof |
| AU2018215678A1 (en) | 2017-02-06 | 2019-08-22 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CA3120858A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| MX2022014637A (en) | 2020-05-20 | 2023-03-03 | Rodeo Therapeutics Corp | Compositions and methods of modulating short-chain dehydrogenase activity. |
| CN112933100B (en) * | 2021-04-27 | 2022-06-24 | 中国人民解放军空军军医大学 | Application of demethyleularmin in leucoderma medicament and ointment thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| EP0302147A1 (en) * | 1987-08-03 | 1989-02-08 | The Procter & Gamble Company | Topical tanning compositions |
| FR2623716B1 (en) * | 1987-11-27 | 1991-04-05 | Lvmh Rech | COMPOSITION BASED ON HYDRATED LIPID LAMID PHASES OR LIPOSOMES CONTAINING TYROSINE OR A TYROSINE DERIVATIVE AND COSMETIC OR PHARMACEUTICAL COMPOSITION, ESPECIALLY DERMATOLOGICAL, WITH PIGMENTANT ACTIVITY, INCORPORATING IT |
| US5352440A (en) * | 1988-03-30 | 1994-10-04 | Trustees Of Boston University | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof |
| DE4124693A1 (en) * | 1991-07-22 | 1993-01-28 | Schering Ag | Use of carbocycline derivs. - esp. iloprost, cicaprost, eptaloprost, beraprost or ciprostene, for treatment of vitiligo |
-
1993
- 1993-10-20 SE SE9303444A patent/SE9303444D0/en unknown
-
1994
- 1994-10-19 WO PCT/SE1994/000985 patent/WO1995011003A1/en not_active Application Discontinuation
- 1994-10-19 JP JP7511697A patent/JPH09504021A/en active Pending
- 1994-10-19 AU AU80086/94A patent/AU8008694A/en not_active Abandoned
- 1994-10-19 CA CA002174655A patent/CA2174655A1/en not_active Abandoned
- 1994-10-19 EP EP94931257A patent/EP0724425A1/en not_active Withdrawn
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986715B2 (en) | 2002-02-04 | 2015-03-24 | Allergan, Inc. | Method of enhancing hair growth |
| US10159631B2 (en) | 2002-02-04 | 2018-12-25 | Allergan, Inc. | Method of enhancing hair growth |
| US8632760B2 (en) | 2002-02-04 | 2014-01-21 | Allergan, Inc. | Method of enhancing hair growth |
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US10188591B2 (en) | 2002-02-04 | 2019-01-29 | Allergan, Inc. | Method of enhancing hair growth |
| US8926953B2 (en) | 2002-02-04 | 2015-01-06 | Allergan, Inc. | Method of enhancing hair growth |
| US8298518B2 (en) | 2002-02-04 | 2012-10-30 | Allergan, Inc. | Method of enhancing hair growth |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US8263054B2 (en) | 2002-02-04 | 2012-09-11 | Allergan, Inc. | Method of enhancing hair growth |
| US9226931B2 (en) | 2002-02-04 | 2016-01-05 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US9750750B2 (en) | 2009-11-09 | 2017-09-05 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9763959B2 (en) | 2009-11-09 | 2017-09-19 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9849140B2 (en) | 2009-11-09 | 2017-12-26 | Allergan, Inc. | Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
Also Published As
| Publication number | Publication date |
|---|---|
| SE9303444D0 (en) | 1993-10-20 |
| WO1995011003A1 (en) | 1995-04-27 |
| JPH09504021A (en) | 1997-04-22 |
| AU8008694A (en) | 1995-05-08 |
| EP0724425A1 (en) | 1996-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2174655A1 (en) | New use of prostaglandins | |
| JP4397973B2 (en) | Topical composition for stimulating hair growth of wrinkles | |
| US10188591B2 (en) | Method of enhancing hair growth | |
| DE68929435T2 (en) | Prostaglandin derivatives used to treat glaucoma or ocular hypertension | |
| US7550508B2 (en) | Prostaglandin analog compositions and methods to treat epithelial-related conditions | |
| JPH09504543A (en) | Cataract prevention methods and preventive measures | |
| US20110112198A1 (en) | Compositions for enhancing hair growth | |
| JP2005511650A (en) | Treatment of skin hyperpigmentation | |
| EP0680761B1 (en) | Topical medicament having cicatrizing activity | |
| EP0436010A1 (en) | Skin composition to repair the efffects of photoaging | |
| US20190029941A1 (en) | Retinoid double conjugate compounds, compositions thereof, and methods for treating of skin conditions | |
| JP4954988B2 (en) | Whitening agent containing aliphatic compounds | |
| CA3075004A1 (en) | Composition for increasing hair growth and reducing hair loss | |
| FR3099057A1 (en) | Inhibitor of the LAT-1 / SLC7A5 transporter for its use for the regulation of skin pigmentation and a composition comprising said inhibitor | |
| CA2700729A1 (en) | Therapeutic agent for vitiligo and method of accelerating pigmentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |